Celltrion Collaborated with Rani Therapeutics for the Development of RT-111 (biosimilar, ustekinumab)
Shots:
- The companies collaborated for the development of RT-111, an orally administered ustekinumab biosimilar
- Under the terms of the license and supply agreement, Celltrion is exclusively supplying Rani with ustekinumab biosimilar drug substance (CT-P43) required for RT-111. Additionally, Rani will get an exclusive license to use CT-P43 for the development and commercialization of RT-111
- Following a P-I clinical trial, Celltrion gets the right of first negotiation to acquire global rights to RT-111. The RaniPill capsule, a form of oral dosing for biologics and drugs was developed by Rani as an alternative to SC or IV inj.
Ref: Globenewswire | Image: Rani Therapeutics
Related News:- Rani Therapeutics Highlighted RT-111 Development Program for Multiple Indications
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
